The advances in psoriasis management currently allow achieving a good control of the
disease. In particular, with the latest developed molecules, available evidence suggests that …

Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity
or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear …

Background Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits
interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab …

Background Guselkumab is a drug used to treat moderate to severe plaque psoriasis.
However, real-life clinical data on its off-label use are limited, especially regarding the …

Introduction Dose escalation and reduction of biologic treatments are frequent in clinical
practice. The aim of this systematic review is to summarise evidence on dose adjustment of …

Study design After one year of maintained PASI-100, the between-dose intervals were
progressively extended, stepping up 3–4 days each month, up to a 21-or 28-day interval …

Background Safety and efficacy of new treatments are analyzed in clinical trials but their
capacity to show potential effects of long‐term treatment and more than short latency of …

Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused
by several complex factors, both environmental and genetic, many of which are still not fully …

Purpose An Italian real-world retrospective study was conducted in patients with psoriasis
(PSO) to evaluate their characteristics, treatment patterns, and biological/targeted synthetic …

Background: Biologics are usually licensed according to the “one dose fits all” principle. It is
therefore suspected that a significant number of patients with psoriasis are overtreated …